Comparing reduced stent strategy with conventional stent treatment for heart attack patients

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)

NA · Hospital Universitario La Fe · NCT06353594

This study tests whether using drug-coated balloons instead of regular stents can help heart attack patients recover better after treatment.

Quick facts

PhaseNA
Study typeInterventional
Enrollment1272 (estimated)
Ages18 Years and up
SexAll
SponsorHospital Universitario La Fe (other)
Locations15 sites (Valencia, Valencia and 14 other locations)
Trial IDNCT06353594 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the effectiveness of a reduced stent strategy using drug-coated balloons (DCB) compared to the conventional approach of using drug-eluting stents (DES) in patients experiencing ST-segment myocardial infarction (STEMI). Patients will be randomly assigned to either the DCB-based strategy or the DES-based strategy after successful guidewire crossing and restoration of blood flow. The study seeks to determine which method provides better outcomes for patients undergoing percutaneous coronary intervention (PCI).

Who should consider this trial

Good fit: Ideal candidates for this study are patients presenting with STEMI who require percutaneous coronary intervention.

Not a fit: Patients with severe comorbidities, such as life expectancy less than one year or significant heart failure, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for heart attack patients, potentially reducing complications associated with stent placement.

How similar studies have performed: Other studies have explored similar approaches in coronary interventions, but the specific reduced stent strategy using DCB in STEMI patients is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

\- Patients presenting with STEMI and indication to undergo pPCI.

Exclusion Criteria:

* Life expectancy \<1 year due 1 to non-cardiac disease.
* Inability to provide informed consent.
* Cardiogenic shock.
* Left ventricular ejection fraction \<15%.
* Left main disease.
* Stent thrombosis
* Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions).
* Patients with chronic total occlusions.
* Untreatable coronary disease.
* Non-identified culprit lesion.
* Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.

Where this trial is running

Valencia, Valencia and 14 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: ST Elevation Myocardial Infarction, STEMI

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.